review Open AccessTop 1% cited
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Journal of Hepatology · 2018 · Vol. 69(1) · pp. 182–236
Peter R. Galle✉(European Association for the Study of Diabetes)Alejandro Forner(European Association for the Study of Diabetes)Josep M. Llovet(European Association for the Study of Diabetes)Vincenzo Mazzaferro(European Association for the Study of Diabetes)Fabio Piscaglia(European Association for the Study of Diabetes)Jean‐Luc Raoul(European Association for the Study of Diabetes)Peter Schirmacher(European Association for the Study of Diabetes)Valérie Vilgrain(European Association for the Study of Diabetes)
Hepatocellular Carcinoma Treatment and PrognosisLiver Disease Diagnosis and TreatmentHepatitis B Virus StudiesHepatocellular carcinomaMedicineClinical PracticeLiver cancerCancerInternal medicineCause of deathHepatocellular cancerIntensive care medicineOncology
MeSH terms
EuropeGastroenterologyCarcinoma, HepatocellularHumansLiver NeoplasmsSocieties, MedicalPractice Guidelines as TopicDisease Management
Citations
11,335
FWCI
568.73
field-weighted impact
References
644
Percentile
100%
vs. same field & year
Citations per year
Cited by
Liver imaging reporting and data system (LI-RADs) of computed tomography in suspected hepatocellular carcinoma
International Journal of Radiology and Diagnostic Imaging · 2024 · 0 citations
EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
Journal of Hepatology · 2024 · 1,354 citations
Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child–Pugh A Liver Function: A Proof-Of-Concept Study
Cancers · 2019 · 293 citations
EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis
Journal of Hepatology · 2017 · 1,393 citations
Biomarkers in Hepatocellular Carcinoma: Diagnosis, Prognosis and Treatment Response Assessment
Cells · 2020 · 489 citations
EASL Clinical Practice Guidelines: Management of alcohol-related liver disease
Journal of Hepatology · 2018 · 883 citations
Hepatocellular carcinoma: clinical frontiers and perspectives
Gut · 2014 · 1,407 citations
The C-Reactive Protein/Albumin Ratio, a Novel Inflammation-Based Prognostic Score, Predicts Outcomes in Patients with Hepatocellular Carcinoma
Annals of Surgical Oncology · 2014 · 435 citations
References
Hepatitis C guidance: AASLD‐IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus
Hepatology · 2015 · 1,379 citations
Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies
Journal of Hepatology · 2005 · 3,114 citations
Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
International Journal of Cancer · 2010 · 1,313 citations
Sorafenib in Advanced Hepatocellular Carcinoma
New England Journal of Medicine · 2008 · 12,835 citations
Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival
Hepatology · 2003 · 3,004 citations
One Thousand Fifty-Six Hepatectomies Without Mortality in 8 Years
Archives of Surgery · 2003 · 831 citations
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
The Lancet Oncology · 2008 · 5,801 citations
Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma
Gastroenterology · 2012 · 3,378 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.